Skip to content
Search

Latest Stories

PDA members favour independent scrutiny of GPhC policies

The Pharmacists’ Defence Association (PDA) members survey revealed that the policies made by the pharmacy regulator should be subject to scrutiny by independent external stakeholders.

The survey was in response to the General Pharmaceutical Council’s (GPhC) 12-week consultation on delivering equality, improving diversity and fostering inclusion.


The survey also indicated that the progress of such scrutiny should be regularly monitored and reports be published.

It further suggested that GPhC should set and publish measurable targets like ethnicity pay gap reporting for evaluating its equality, diversity and inclusivity (EDI) strategy.

The GPhC’s draft five-year strategy outlines three themes.

The first target is to make regulatory decisions that are demonstrably fair, lawful, and free from discrimination and bias.

The second is to proactively help tackle discrimination in all pharmacy settings and ensure that everyone gets access to person-centred care.

The third is to lead by example and demonstrate best practice within the organisation.

The three themes have several objectives and proposed outcomes, but do not detail about any tangible measurable outcomes.

“As we developed our response to this important consultation, we wanted to hear from members what they thought was important to give them confidence and assurance in their regulator’s EDI policies. Clearly, having clear measurable goals and independent scrutiny is a top priority for them,” Alison Jones, director of stakeholder engagement at the PDA said.

She noted that pharmacists often face issues caused by discrimination against them due to their race, gender, disability, or sexual identity.

"It is vitally important that the GPhC has robust EDI policies in place to provide confidence to registrants that their rights are protected, that any decisions made are done so fairly and without discrimination, and that the organisation holds itself accountable to the same high standards that it expects of others,” Jones added.

The GPhC’s consultation closes on July 12.

More For You

Scottish community pharmacist working in high street pharmacy with supportive environment

The PDA wants investment to reach those who deliver services to patients every day

Pic credit: iStock

Funding boost in Scotland “needs to work for not just pharmacy owners but pharmacists too”, says PDA

An increase in funding for community pharmacies in Scotland needs to lead to a greater focus on supporting pharmacists rather than “simply sustain business models”, according to the Pharmacy Defence Association (PDA).

Earlier this week, Community Pharmacy Scotland (CPS) accepted the Scottish government’s initial financial offer for the 2025/26 fiscal year, securing a guaranteed minimum reimbursement of £120 million for community pharmacies — up from £110 million from 2024/25.

Keep ReadingShow less
Aspire Pharma acquisition boosts access to essential medicines for NHS patients in the UK

The acquisition is expected to further drive the company’s growth.

gettyimages

Aspire acquires UK distribution rights from Tetris

Aspire Pharma Limited, one of the UK’s fastest-growing specialty niche generics companies, has announced the acquisition of UK distribution rights to a number of products from Tetris Pharma, a subsidiary of Arecor Therapeutics.

These include products used in the treatment of bacterial infections—such as injectable and intravenous antibiotics—as well as a medicine indicated for acute myocardial infarction (MI) and deep vein thrombosis (DVT).

Keep ReadingShow less
GP surgery upgrades for annual appointments

The surgeries will have additional space to “see more patients, boost productivity and improve patient care”

Pic credit: iStock

GP surgery upgrades to create 8.3 million more annual appointments

Over 1,000 GP surgeries will have their premises modernised to meet the needs of a further 8.3 million appointments each year, the government has announced.

Backed by a cash injection of over £102 million, the surgeries will have additional space to “see more patients, boost productivity and improve patient care”.

Keep ReadingShow less
Wales boosts funding for pharmacy-led UTI and sore throat test services

The sore throat test (STTT) and treat service will be widely available

Pic credit: istock

Welsh pharmacies receive funding boost for clinical services

Two key clinical services will be available in 99 per cent of community pharmacies across Wales after a boost in funding.

The sore throat test (STTT) and treat service and the urinary tract infection (UTI) service have both benefitted from contractual negotiations between the Welsh Government and Community Pharmacy Wales (CPW).

Keep ReadingShow less
Paul Bennett
Paul Bennett, CEO, Royal Pharmaceutical Society
Paul Bennett, CEO, Royal Pharmaceutical Society

Pharmacists need to take advantage of independent prescribing pathways, says Bennett

Independent prescribing will be a “significant point” in the history of community pharmacy, according to Royal Pharmaceutical Society chief executive Paul Bennett.

Last month, the RPS announced the launch of a comprehensive new prescribing development programme to support pharmacists across all stages of their prescribing careers.

Keep ReadingShow less